Description: The objective of the fund is to provide exposure to a basket of stocks of companies that are actively engaged in the research, development and/or manufacturing of orphan drugs. The Index selects stocks that meet certain size and liquidity requirements using a two-fold approach that is primarily based on the trend in the valuation of a companyâs orphan drug portfolio and its overall revenue forecasts.
Exchange: LSE
Country: UK
Currency: Pence sterling (p)
Category: Sector Equity Biotechnology
| Asset Allocation | |||
|---|---|---|---|
| Asset Class | Long % | Short % | Net Assets |
| Stock US | 57.98 | 0.00 | 57.98 |
| Stock non-US | 41.88 | 0.00 | 41.88 |
| Cash | 0.14 | 0.00 | 0.14 |
| Sector Weights | ||
|---|---|---|
| Sector | Equity % | Relative to Category |
| Healthcare | 100.00 | 99.95 |
| World Regions | ||
|---|---|---|
| Region | Equity % | Relative to Category |
| North America | 58.06 | 86.85 |
| Europe Developed | 23.93 | 7.33 |
| Japan | 5.86 | 0.63 |
| Asia Emerging | 4.56 | 2.50 |
| Australasia | 3.98 | 0.14 |
| Asia Developed | 3.60 | 0.32 |
| United Kingdom | 0.00 | 2.20 |
| Africa/Middle East | 0.00 | 0.02 |